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Abstract
Background: GATA-binding protein 3 (GATA3) has been identified as a sensitive marker for breast carcinoma but
its sensitivity in primary genital extramammary Paget diseases (EMPDs) has not been well studied.
Methods: Here we investigated immunohistochemical expression of GATA3 in 72 primary genital EMPDs (35 from
female, 37 from male; 45 with intraepithelial disease only, 26 with both intraepithelial disease and invasive
adenocarcinoma including 14 also metastasis, 1 with metastatic adenocarcinoma only for study). We also compared
GATA3 to gross cystic disease fluid protein 15 (GCDFP15) for their sensitivity.
Results: Positive GATA3 staining was seen in all 71 (100%) intraepithelial diseases, 25/26 (96%; female 10/10,
male 15/16) invasive adenocarcinomas and 14/15 (93%; female 3/3, male 11/12) metastatic adenocarcinomas,
respectively. Positive GCDFP15 staining was seen in 46/71 (65%; female 28/34 or 82%, male 18/37 or 49%) intraepithelial
diseases, 20/26 (77%; female 9/10, male 11/16) invasive adenocarcinomas, and 12/15 (80%; female 2/3, male 10/12)
metastatic adenocarcinomas, respectively (GATA3 versus GCDFP15: p < 0.01 for both intraepithelial disease and invasive
adenocarcinoma, p = 0.28 for metastatic adenocarcinoma). In positive-stained cases, GATA3 stained more tumor cells
than GCDFP15 (79% versus 25% for intraepithelial disease, 71% vs 34% for invasive adenocarcinoma, 73% vs 50% for
metastatic adenocarcinoma, p < 0.01 for all 3 components).
Conclusions: Our findings indicate that GATA3 is a very sensitive marker for primary genital EMPDs and is more
sensitive than GCDFP15.
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Background
Paget disease (PD) is a distinct intraepidermal adenocarcinoma with a pagetoid growth pattern. PDs are classified
as mammary and extramammary subtypes according to
their locations and their relationship to breast [1, 2].
Mammary PDs account for 90% of the PDs occurring on
the skin of nipple/areola complex and most of them represent tumor spread to the epidermis from an underlying invasive ductal carcinoma (53–60%) or ductal carcinoma in
situ (24–43%). Compared to breast PD, primary extramammary PDs (EMPDs) are relatively uncommon and
their histogenesis is less clear [1, 2].
Primary EMPDS are found in areas rich in apocrine
glands. The most common site of primary EMPDs is
vulva followed by perianal skin, scrotum and penis, and
axilla etc. [1–6]. In women, more than 80% of primary
EMPDs are in the vulva [1–4, 6]. In men, approximately
half of EMPDs are in the penoscrotal region [4–8]. Most
primary EMPDs are intraepithelial at their initial presentation (type Ia disease) but some have both intraepithelial disease and invasive adenocarcinoma i.e. invasive
EMPDs [1–11]. The invasive adenocarcinomas seen in
primary EMPDs include those arising from intraepithelial EMPD (type Ib disease) and those giving rise to the
intraepithelial disease (type Ic disease, underlying adenocarcinoma with subsequent epidermal involvement i.e.
Paget disease as manifestation of an underlying adenocarcinoma) [3]. Among patients with invasive EMPDs
(type Ib and type Ic), 20% to 40% had lymph node metastasis [4–7, 9, 11]. Up to 17% to 50% patients with invasive EMPDs also develop concurrent or subsequent
distant metastasis [4, 5, 7, 9–12].
Primary EMPDs should be distinguished from secondary EMPDs given their different treatment and prognosis
[3]. Secondary EMPD is usually the result of intraepithelial spread from a visceral carcinoma located elsewhere,
with the gastrointestinal tract (colorectum) or urogenital
tract (urinary bladder, prostate) being the most 2 common sources [1–3, 9, 13–17]. EMPDs may also pose
some diagnostic challenges in metastatic sites as they
morphologically may mimic other tumors such as urothelial carcinoma and breast carcinoma. This diagnostic challenge is further complicated by the fact that patients with
EMPDs have an increased risk of developing secondary
primary tumors in which breast carcinoma, colorectal
adenocarcinoma and urothelial carcinoma are among the
most common ones [4–6, 9, 14–17].
Given the overlapping morphologic features between
primary EMPDs and secondary ones, and between metastatic EMPDs and their mimics in metastatic sites, immunohistochemical markers are often needed to facilitate the
correct diagnosis. Several immunohistochemical markers,
including cytokeratin 7, carcinoembryonic antigen, androgen receptor and c-erbB2 (HER2), have been used for
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diagnosing primary EMPDs, however, their specificity is
relatively low [18–20] and therefore limited their diagnostic utility in metastatic setting. Gross cystic duct fluid
protein 15 (GCDFP15, also known as BRST-2) shows
relatively high specificity for EMPDs but its sensitivity
was only 60% to 85% and in many cases the staining
was focal [21–26]. Primary EMPD is analogous to breast
Paget disease. Recently a transcription factor GATAbinding protein 3 (GATA3) has been identified as a very
sensitive marker for breast carcinoma, both in both
primary and metastatic sites [27–31]. GATA3 was also
reported to be highly expressed in apocrine glands and
adnexal tumors [30]. Apocrine gland has been proposed
as the origin of primary EPMDs according to one theory
[1, 2, 21]. These findings suggest that GATA3 might be a
sensitive marker for primary EMPDs. In the literature,
there was only one recent report of GATA3 in 11 vulvar
primary EMPDs [32].
In this study, using immunohistochemical staining we
investigated the expression of GATA3 in a large series of
72 primary EMPDs (45 with intraepithelial disease only,
26 with both intraepithelial disease and invasive adenocarcinoma including 14 also with lymph node metastasis,
1 with metastatic adenocarcinoma only for study) in male
and female genital regions to explore the potential diagnostic utility of GATA3 in these tumors. We also compared GATA3 to GCDFP15 in these tumors for their
sensitivity.

Methods
Materials

The surgical pathology archives of the authors’ hospitals
were searched for primary EMPDs in male and female
genital regions. A total of 72 surgically resected cases with
confirmed diagnosis of primary EMPDs in the genital region were included for this study: 35 from female and 37
from male patients. All 35 female cases were from vulva,
including 24 with intraepithelial disease only (type Ia disease), 10 with both intraepithelial disease and invasive
adenocarcinoma (5 type Ib, 5 type Ic, 2/5 type Ic cases
with metastatic adenocarcinoma in nodes) and 1 with only
metastatic node disease for study (history of primary vulvar EMPD). No breast tissue or mammary-like gland was
present in the adjacent vulva tissue in any of these female
cases. The 37 male cases included 3 from penis, 1 from
perineum, and 33 from the scrotum. Twenty-one (21 or
57%) male cases were intraepithelial diseases, 16 (43%)
cases had both intraepithelial disease and invasive adenocarcinoma (14 type Ib, 2 type Ic; 12/16 also with nodal
metastasis including 11/14 type Ib and 1/2 type Ic).
Immunohistochemical staining

One to two formalin-fixed, paraffin-embedded full tissue
blocks from each case were retrieved to generate 4 um
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unstained slides for immunohistochemical staining on a
Ventana Benchmark-XT automated stainer using the
Ventana ultraView DAB detection kit. The antibody to
GATA3 is a mouse monoclonal antibody (clone L50–
823, prediluted, Biocare, Concord, CA 94520). The antibody to GCDFP15 was a rabbit monoclonal antibody
(clone EP95, prediluted, Rocklin, CA 95677). The automatic immunohistochemical reaction was performed
with Ventana Cell Conditioning Solution 1 (CC1) at
pH 6.0. The primary antibody (antibody to GATA3, antibody to GCDFP15) was incubated at 37 degrees for
24 min. Positive control (breast ductal carcinoma as
positive control) and negative control (incubation with
secondary antibody only) were included for each run of
immunostains. Only nuclear staining was considered
positive for GATA3. The staining pattern for GCDFP15
is cytoplasmic. The percentage of tumor cells labeled
was semi-quantitatively scored as 0 (<1% tumor cell
staining), 1+ (1–25%), 2+ (26–50%), 3+ (51–75%), and 4
+ (76–100%).
Statistical analysis

The Fisher exact test was used to compare the staining
pattern for GATA3 with GCDFP15, and paired t-test
was used to compare the mean percentage of tumor cells
stained with GATA3 with GCDFP15 in the intraepithelial component, invasive component and metastatic
components of EMPDs. A P-value of <0.05 was considered statistically significant.

Results
Expression of GATA3 and GCDFP15 in female primary
extramammary Paget diseases

Among the 35 vulvar EMPDs, 24 had intraepithelial disease only, 10 had both intraepithelial disease and invasive

adenocarcinoma (2 also had regional lymph node metastasis) and 1 had only the metastatic adenocarcinoma in one
lymph node for study (history of vulvar primary EMPD).
Among the 10 cases with both intraepithelial disease and
invasive adenocarcinoma, 5 were type Ib and 5 were type
Ic diseases (4 apocrine carcinomas and 1 eccrine carcinoma). The staining results of GATA3 and GCDFP15 for
each component of vulvar extra-mammary diseases are
summarized in Table 1.
All 34 intraepithelial disease components showed positive GATA3 staining (34/34, 100%), including 1+ in 2
(6%), 2+ in 1 (3%), 3+ in 3 (9%) and 4+ in 28 (82%), with
almost all cases demonstrating moderate to strong nuclear staining (Fig. 1). The invasive adenocarcinoma
showed positive GATA3 staining in all 10 cases (2+ in 2,
4+ in 8) (Figs. 2, 3). All 3 metastatic adenocarcinomas
from vulvar EMPDs showed 4+ GATA3 staining (Fig. 2).
Positive GCDFP15 staining was seen in 28 of 34 (82%)
intraepithelial disease components (1+ in 12/28, 2+ in 4/
28, 3+ in 4/28, 4+ in 8/28) and 9 of 10 (90%) invasive
adenocarcinomas (1+ in 3/10, 3+ in 1/10, and 4+ in 5/10;
5/5 type Ib disease, 4/5 type Ic disease) (Table 1, Figs. 2,
3). The only invasive adenocarcinoma that was negative
for GCDFP 15 staining was the eccrine carcinoma (type Ic
disease). Two of the 3 (66%) metastatic adenocarcinomas
showed positive GCDFP15 staining (1+, 4+) (Fig. 2).
Expression of GATA3 and GCDFP15 in male primary
extramammary Paget diseases

Among the 37 cases of male extra-mammary Paget diseases, 33 were from the scrotum, 3 from the penis and 1
from the perineum. Twenty-one (57%) had intraepithelial disease only. The remaining 16 cases (16/37 or 43%)
had both intraepithelial disease and invasive adenocarcinoma (14 type Ib, 2 type Ic) including 12 (12/16, 80%)

Table 1 Immunohistochemical staining results of GATA3 and GCDFP15 in primary vulvar extramammary Paget diseases
Disease Component

GATA3 staininga
0 1+

Intraepithelial disease
(N = 34)
Type Ia (N = 24)

0 2 (6%) 1 (3%)
1

Type Ib (N = 5)
Type Ic (N = 5)
Invasive adenocarcinoma
(N = 10)

2+

3+

0

2 (20%) 0

20

4

8

4

1

3

4

1

1

8 (80%)

10 (10%)

1 (10%) 3 (30%)

5
2
0

1+

2+

3+

4+

Total

3

type Ib (N = 5)
type Ic (N = 5)

Total

12 (35%) 4 (12%) 4 (12%) 8 (24%) 28 (82%) 0.0004#

1

Metastatic adenocarcinoma 0 0
(N = 3)

4+

3 (9%) 28 (82%) 34 (100%) 6 (8%)

1
0 0

P value

GCDFP15 staininga

0

4

1

3 (100%) 3 (100%)

1 (33%) 1 (33%)

5
1

1
0

1

3

3

2

1 (10%) 5 (50%) 9 (90%)
1

2

0.1035#

3
2

0

0

1 (33%) 2 (67%)

not
applicable

a
The staining is semi-quantitatively as follows: 0: <1% tumor cell staining; 1+: 1–25% tumor cells staining; 2+: 26–50% tumor cells staining; 3+: 51–75% tumor cells
staining; 4+: 76–100% tumor cells staining. NA non-applicable due to small number
#
p value refers to comparison of staining patterns (0,1+,2+,3+,4+) not percentage of total positives
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Fig. 1 Immunohistochemical staining of GATA3 and GCDFP15 in primary extramammary Paget diseases in the genital region: all intraepithelial
diseases in both genders (A1, vulva; B1, scrotum) were positive for GATA3 (A2, B2). Most of intraepithelial diseases (50% male, 82% female) were
also positive for GCDFP15 (A3, B3). GCDFP15 staining is often focal (B3)

with lymph node metastases. The staining results of
GATA3 and GCDFP15 for each component of male
extra-mammary diseases are summarized in Table 2.
Positive GATA3 staining was seen in all 37 intraepithelial disease components (100%), including 1+ in 4
(11%), 2+ in 2 (6%), 3+ in 2 (6%), and 4+ in 29 (78%)
(Fig. 1). The invasive adenocarcinomas showed positive
GATA3 staining in 15/16 (94%) cases including 1+ in 2
(12%), 2+ in 2 (12%), 3+ in 1 (6%) and 4+ in 10 (63%)
(Fig. 2). The invasive adenocarcinoma in type Ib disease
was positive for GATA3 in 13/14 cases (93%). The
underlying invasive adenocarcinomas in 2 type Ic
EMPDs were both positive for GATA3 (2+, 4+). Positive
GATA3 staining was seen in 11/12 (92%) metastatic
adenocarcinomas, including 1+ in 1 (8%), 2+ in 1 (8%), 3
+ in 1 (8%) and 4+ in 8 cases (67%) (Fig. 2).
Positive GCDFP15 staining was seen in 18 of 37 (51%)
intraepithelial disease components including 1+ in 12
(32%), 2+ in 4 (11%), and 4+ in 2 (6%) (Fig. 1). The invasive adenocarcinomas showed positive GCDFP15 staining in 11 of 16 (69%) cases including 1+ in 6 (38%), 2+
in 1 (6%) and 4+ in 4 (25%). The invasive adenocarcinoma in Type Ib disease was positive for GCDFP15 in 9/
14 (64%, 1+ in 5/9, 4+ in 4/9) cases. The 2 invasive
adenocarcinomas in type IC EMPDs showed positive
GCDFP15 staining in both (1+, 2+). Positive GCDFP15
was seen in 10 of 12 (83%) metastatic adenocarcinomas
(1+ in 3/12, 2+ in 2/12, 3+ in 1/12, 4+ in 4/12) (Fig. 2).
Comparison of GATA3 to GCDFP15 in primary genital
extramammary Paget diseases

Among the 71 intraepithelial diseases (34 from female,
37 from male), all (100%) showed GATA3 staining
whereas only 46 of them (46/71 or 65%, female 28/34 or

82%, male 18/37 or 51%) showed positive GCDFP15
staining (p < 0.0001). Among the invasive adenocarcinomas, positive GATA3 and GCDFP15 staining was seen
in 25/26 (96%) and 18/26 (69%) cases, respectively
(p = 0.01). Among the 15 metastatic adenocarcinomas,
14 (93%) showed positive GATA3 staining and 12 (80%)
showed positive GCDFP15 staining (p = 0.2825).
Among the cases with positive immunohistochemical
staining, the mean percentage of positively stained
tumor cells in the intraepithelial diseases was 79% (female 83%, male 76%) for GATA3 and it was 25% (female
35%, male 10%) for GCDFP15 (p < 0.001). As far as the
invasive adenocarcinomas were concerned, the mean
percentage of tumor cells positive for GATA3 and
GCDFP15 was 71% (female 76%, male 68%) and 34% (female 42%, male 34%), respectively (p < 0.001). The mean
percentage of GATA3-positive metastatic adenocarcinoma cells was 73% (female 90%, male 68%) and it was
50% for GCDFP15 (female 65%, male 48%) (p < 0.01).
Expression of GATA3 in normal epidermal cells

Positive GATA3 staining was seen in some normal epidermal cells in 22/34 (65%) female and 22/37 (60%)
cases, respectively, mainly in the spinous layer (typically
focal but occasionally diffuse) with occasionally in the
basal layer. Among the GATA3 positive cases, the
GATA3 staining intensity in the normal epidermal cells
was weaker than that in PD in 16/22 (73%) female and
17/22 (77%) cases, respectively. Similar GATA3 staining
intensity was seen in the normal epidermal cells and in
the intraepithelial PD cells in 6 of 22 (27%) female and 5
of 22 (23%) male cases, respectively. The intraepithelial
PD cells typically have larger nuclei than normal epidermal cells. However, in 2 cases in each gender, the
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Fig. 2 The invasive adenocarcinoma in type Ib disease (primary extramammary Paget disease with invasive adenocarcinoma) (A1: vulva, with
intracytoplasmic mucin; B1: scrotum) showed positive GATA3 staining in all but one cases (A2, B2) (A2 also with intraepithelial disease). Most of
such invasive adenocarcinomas were also positive for GCDFP15 staining (A3, B3). All 3 metastatic adenocarcinomas from vulvar (C1) and 11 of 12
metastatic adenocarcinomas from penoscrotal (D1) extramammary Paget diseases were positive for GATA3 (C2, D2) and most of them were also
positive for GCDFP15 (C3, D3). GATA3 stains more tumor cells than GCDFP15 in some cases (D2, D3)

intraepithelial PD cells focally have small nuclei and in
these areas it is difficult to distinguish the intraepithelial
PD cells from normal epidermal cells just based on immunohistochemical staining. Their distinction relies on
the growth pattern.

Discussion
In this study, we investigated the immunohistochemical
expression of GATA3 in a large series of 72 primary
EMPDs in male and female genital regions. We found
that GATA3 was highly expressed in the primary genital
EMPDs. The high sensitivity of GATA3 is not only
present in the intraepithelial disease (100%) but also in
the invasive adenocarcinomas (96%) and metastatic
adenocarcinomas (93%). These results indicate that
GATA3 is a very sensitive marker for primary EMPDs in
the genital regions.

GATA3 is a zinc-finger transcription factor involved in
embryogenesis, cell proliferation and differentiation in
multiple human tissues and organs, including breast, genitourinary system, parathyroid, skin, central nervous and
hematopoietic systems [33–36]. In 2007, Higgins et al.
found that GATA3 was a sensitive diagnostic marker for
urothelial carcinoma [37]. Since then, there has been
growing evidence that GATA3 could serve as a relatively
sensitive diagnostic marker for breast carcinomas, parathyroid tumors, trophoblastic tumors, mesonephric adenocarcinomas, paragangliomas and pheochromocytomas
etc. [28–31, 38–42]. Other tumors with a less frequent
expression of GATA3 include salivary gland tumors,
malignant mesotheliomas, pancreatic adenocarcinomas,
skin squamous cell carcinomas, skin adnexal tumors, renal
oncocytomas, chromophobe renal cell carcinomas, and
yolk sac tumors [28–30]. Morbeck D et al. recently reported positive GATA3 expression in all 11 vulvar primary
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Fig. 3 Immunohistochemical staining of GATA3 and GCDFP15 in a vulvar primary extra-mammary Paget disease with an underlying apocrine
adenocarcinoma (type Ic disease). The underlying apocrine adenocarcinoma formed a mass in the dermis and subcutaneous tissue but it eroded
the epidermis (a) and grew in a pagetoid pattern within the adjacent epidermis (b, g). The underlying adenocarcinoma showed nests, solid and
glandular growth patterns with some cribriform glands (c, d). Cytoplasmic apical apocrine snouts were apparent (d). Both the underlying invasive
apocrine adenocarcinoma (d) and the overlying intraepithelial Paget disease (g) were positive for GATA3 (e, h) and GCDFP15 (f, i). Similar GATA3
findings were also observed in penoscrotal type Ic diseases

EMPDs (4 with invasive carcinoma) [32]. They did not
include any metastatic adenocarcinoma from vulvar Paget
disease. They did not study male genital EMPDs, either.
Our findings and that of Morbeck et al. [32] add primary
genital EMPDs to the list of tumors with high expression
of GATA3. High expression of GATA3 in EMPDs has

some diagnostic implications, both for primary EMPDs
and their metastasis.
Distinguishing primary from secondary EMPDs is clinically critical given their different treatment and prognosis
[3, 9]. Secondary EMPD in the genital region is usually the
result of intraepithelial spread from a visceral carcinoma,

Table 2 Immunohistochemical staining results of GATA3 and GCDFP15 in primary male genital extramammary Paget diseases
Disease Component
Intraepithelial disease
(N = 37)

GATA3 staininga
0

1+

0

4 (11%) 2 (6%)

Type Ia (N = 21)

1

Type Ib (N = 14)

3

type Ib (N = 14)

3+

4+

Total

1+

2

17
1

7

1

1

1
2 (13%) 2 (13%) 1 (6%) 10 (63%) 15 (94%)
(6%)

5 (31%)

6 (38%)

1

5

2

Metastatic adenocarcinoma 1
1 (8%)
(N = 12)
(8%)

1
1
1 (8%)

3+

1

9
1

1 (8%) 8 (67%)

11 (92%)

2 (17%)

4+

Total

2 (6%)

18 (49%) < 0.001

4

8

1

type Ic (N = 2)

P value
2+

2 (6%) 29 (78%) 37 (100%) 19 (51%) 12 (32%) 4 (11%) 0
20

1

0

1

Type Ic (N = 2)
Invasive adenocarcinoma
(N = 16)

2+

GCDFP15 staininga

4

1 (6%)

5

2

0

4 (25%) 11 (69%)

0.062

4

1

1

3 (25%)

2 (17%) 1 (8%) 4 (33%) 10 (83%)

0.277

a
The staining is semi-quantitatively scored as follows: 0: < 1% tumor cell staining; 1+: 1–25% tumor cells staining; 2+: 26–50% tumor cells staining; 3+: 51–75%
tumor cells staining; 4+: 76–100% tumor cells staining
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with urogenital tract (urothelial carcinoma, prostate) and
the gastrointestinal tract (distal colon, rectum) being the
most 2 common sources [1–3, 6, 9, 12–16]. In females,
secondary EMPD in vulva caused by urothelial carcinoma
typically involves periurethral vulvar vestibule but it may
extend to the adjacent vulvar skin and it may also become
invasive [1–3, 6, 9, 12–16]. In males, both urothelial carcinoma and prostate carcinoma may involve scrotum in
an intraepithelial pagetoid fashion [43–45]. Rarely urothelial carcinoma [43, 46] and prostate adenocarcinoma
[43, 47, 48] may recur in the penis as a secondary
EMPD. Since both primary EMPDs and urothelial
carcinomas are positive for GATA3, GAT3 is not useful in distinguishing primary EMPDs from secondary
EMPD caused by urothelial carcinoma and other
markers should be sought for this purpose. Urothelial
carcinomas are often positive for uroplakin-III, p63
and p40 whereas EMPDs have an opposite immunohistochemical profile [49–51]. GCDFP15 is often positive in primary EMPDs [20–26] but it is only rarely
positive in urothelial carcinoma [43, 52]. Secondary
EMPD caused by prostatic adenocarcinoma can be
distinguished from primary EMPD by p501S (prostein)
and GATA3. Prostatic adenocarcinoma is positive for
p501S but negative for GATA3 whereas EMPD shows an
opposite profile [28–30, 43, 53]. Prostatic adenocarcinoma
can be rarely positive for GCDFP15 and primary EMPDs
can show positive prostate specific antigen (PSA) staining
in as many as 30% cases [43, 53]. Therefore, one cannot
rely on PSA or GCDFP15 to distinguish primary EMPD
from secondary PD caused by prostatic adenocarcinoma.
Secondary EMPDs from anorectal adenocarcinomas typically extend from perianal skin to the vulva or scrotum
[1–6, 9, 43, 44]. GATA3 is negative in colorectal
adenocarcinoma [28–30] and therefore is useful to
distinguish primary genital EMPD from secondary
EMPD due to colorectal adenocarcinoma. It should
be pointed out that primary EMPDs can be rarely
positive for CDX2 (3%) [43]. GCDFP15 is negative in
colorectal adenocarcinomas [43]. Anorectal adenocarcinoma and primary vulvar EMPDs showed overlapping profiles in CK7 and CK20 though CK7 negativity
favors the former and CK20 negativity favors the latter [43]. In the genital area, rare pagetoid squamous
cell carcinoma in situ can closely mimic intraepithelial EMPD [54, 55] and may be misdiagnosed as such
[54]. Since some squamous cell carcinomas and normal epidermal cells are positive for GATA3 [28–30],
GATA3 is not useful to distinguish primary EMPD
from pagetoid squamous cell carcinoma in situ. Instead
P63 should be used in this scenario (p63 negative in primary EMPD but positive in pagetoid squamous cell carcinoma in situ) [50, 51]. Lastly, melanoma in situ may
closely mimic primary EMPD and rare pigmented primary
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EMPD has been reported [56, 57]. Melanoma in situ was
negative for GATA3 [28–30] but positive for S100,
melan-A and HMB45 whereas EMPD had an opposite
immunoprofile.
Although most primary EMPDs are intraepithelial,
approximately 4% to 20% primary vulvar EMPDs
[1–4, 9, 13, 15, 16] and 26% to 61% primary penoscrotal EMPDs were invasive at the time of presentation
[5, 7, 8, 10, 58–61]. Some of these invasive adenocarcinomas arise from the intraepithelial EMPD (type Ib primary
EMPDs) whereas others are underlying adenocarcinomas
which showed secondary epidermotropism (type Ic primary EMPDs) [3, 6, 8, 9, 14–16]. In vulva, it is estimated
that type Ic EMPDs account for at least 10–30% invasive
EMPDs [1–3, 8, 9, 15, 16, 62]. Rare type Ic primary EMPD
in penoscrotum has also been reported [63] and two of
our cases belong to this category. Type Ic EMPDs were reported to be associated with a worse prognosis than type
Ib EMPDs [3, 9] and therefore pathologists should attempt to specify the subtypes of primary invasive EMPDs
(Ib versus Ic). However, it is not always feasible to distinguish them. Our findings indicate that type Ib and apocrine type Ic diseases cannot be distinguished by their
GATA3 and GCDFP15 immunoprofile given their similar
profile for these two markers. Type Ic EMPDs are predominantly of apocrine type, but other types of adenocarcinomas may also rarely give rise to type Ic EMPDs
including eccrine sweat gland adenocarcinoma [64],
Bartholin gland adenocarcinoma [65], and adenocarcinomas of mammary-like glands [66, 67] etc. One of the invasive adenocarcinomas in vulvar type Ic EMPDs in our
study was an eccrine carcinoma. Cutaneous eccrine carcinomas were positive for GATA3 in 36% to 68% cases
[68, 69]. The only eccrine carcinoma in our study showed
4+ GATA3 staining (>75% cells). Thus, GATA3 immunostaining cannot distinguish type Ib EMPDs from apocrine
and eccrine type Ic primary EMPDs. Their distinction relies on morphology and other markers such as p63 and
GCDFP15. Eccrine carcinomas were often positive p63
(85% to 89%) whereas primary type Ib EMPDs were not
[68, 69]. Eccrine carcinomas were only rarely positive for
GCDFP15 (5%) [69]. Adenocarcinoma of mammary-like
gland in the vulva is rare and its diagnosis requires the
presence of a transition zone between normal mammarylike glands and adenocarcinoma [66, 67, 70]. Morphologically it is similar to breast carcinoma. Both ductal type
[66] and lobular-like [67] mammary-like carcinomas with
Paget’s disease (type Ic primary EMPD) have been reported. Although there has been no report of GATA3 in
vulvar adenocarcinoma of mammary-like glands, it is conceivable that the vast majority of these tumors will be
positive for GATA3 as in breast carcinoma. As expected,
two thirds of vulvar mammary-like carcinomas were also
positive for GCDFP15 [70]. For these reasons, rare type IC
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primary EMPD due to mammary-like carcinoma cannot
be distinguished from type Ib EMPD or type IC EMPD
due to sweat gland adenocarcinoma by GATA3 and
GCDFP15 immunostaining. Primary type Ic EMPDs
caused by underlying apocrine carcinomas were often
negative for ER and PR. In contrast, vulvar mammarylike carcinomas were often positive for these two
markers [66, 67, 70–72].
Among patients with invasive EMPDs (type Ib and Ic),
some will develop metastatic disease at the time of presentation or in their subsequent disease courses. In the SEER
data, 17.1% patients with invasive EMPDs have lymph
node metastasis (male 16.0%, female 17.6%) and 2.5% have
distant metastasis (male 3.8%, female 1.9%) at presentation
[4]. In a recent Japanese study of 301 primary invasive
EMPDs (both male and female), 114 (37%) had metastasis
including 20% node metastasis and 17% distant metastasis
(16% with both nodal and distant metastasis) [12]. Lymph
nodes metastasis typically involved inguinofemoral nodes
but pelvic and para-aortic nodes were also involved in
some patients [9–11, 22, 58–62]. Distant metastatic
sites include bone, lung, liver, lung, brain and muscle
[9, 58–62]. Invasive EMPDs were morphologically
similar to other types of tumors especially breast carcinoma and urothelial carcinoma, and therefore they may
pose some diagnostic difficulty in metastasis, which can
be further complicated by the fact that patients with primary EMPDs have an increased risk of developing other
types of secondary primary tumors (overall 5–8% chance).
Breast carcinoma and urothelial carcinoma are among the
most common secondary tumors in these patients, and
they can occur either before or after the diagnosis of primary EMPDs [6, 9, 12, 14–17, 58–60, 62]. In patients with
both a primary invasive EMPD and another type of tumor
(particularly urothelial and breast carcinoma), the differential diagnosis for a metastatic tumor with positive
GATA3 staining should also include metastatic primary
EMPDs in the list of differential diagnosis. A panel of immunohistochemical markers should be used to facilitate
the correct diagnosis.
GCDFP15 was a useful marker for primary EMPDs
but its sensitivity was 60% to 85% [20–26]. In this study,
we showed that GATA3 is relatively more sensitive than
GCDFP15 for primary EMPDs, especially in male patients. Our study is the largest series of primary EMPDs
with GCDFP15 staining. It is interesting to note that
GCDFP15 stains a higher percentage of primary EMPDs
in female patients than male patients.
Although GATA3 is a sensitive marker for primary
genital EMPDs, it should be pointed out that it is not
specific for these tumors. As described above and
reviewed elsewhere, several other types of tumors including urothelial carcinoma, breast carcinoma, paragangliomas/pheochromocytomas, trophoblastic tumors, and
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mesonephric adenocarcinomas are often positive for
GATA3 [28–31, 38–42]. In this sense, GATA3 is less
specific than GCDFP15 for primary genital EMPDs. In
difficult cases particularly in metastasis, both GATA3
and GCDFP15 should be used in conjunction to avoid
misdiagnosis.
Lastly, high expression of GATA3 in primary EMPDs
may also help shed some lights on the histogenesis of
these tumors. Currently there are 3 theories: intraepidermal origin of adnexal origin such as apocrine glands,
multipotent stem cells in the epidermis or infundibular
stem cells from hair follicles [1, 2, 20, 73]. Positive staining for both GATA3 and GCDFP15 in primary EMPDs
probably favors the first theory.
One limitation of our study is that we did not include
genital secondary EMPDs. Secondary EMPDs are rare
and it is difficult to collect a meaningful number of cases
to do a comparison study. The two most common types
of carcinomas that cause secondary EMPDs are urothelial carcinoma and colorectal carcinoma [1–3, 9, 13–17].
As discussed above, GATA3 immunoreactivity was seen
in most urothelial carcinomas but not in colorectal carcinomas [28–30, 37].

Conclusions
In summary, we investigated immunohistochemical expression of GATA3 in a large series of 72 primary
EMPDs in the male and female genital regions. Our
findings show that GATA3 is a very sensitive marker for
genital primary EMPDs and is more sensitive than
GCDFP15. Although GATA3 is highly sensitive for primary EMPDs, it is not specific for these tumors. GATA3
staining cannot distinguish intraepithelial PD from pagetoid squamous cell carcinoma in situ or primary EMPD
from secondary EMPD caused by urothelial carcinoma.
GATA3 staining can be used to distinguish primary
EMPD from pagetoid melanoma in situ and secondary
EMPD caused by colorectal carcinoma. In the metastatic
setting, GATA3-positive tumors should include metastatic adenocarcinoma originated from PD.
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